Dr. Zhao Mingfeng has over 20 years of clinical and leadership experience in hematology, specializing in the diagnosis and treatment of complex malignant and non-malignant hematological disorders. His main areas of clinical expertise include acute and chronic leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and aplastic anemia.
A major focus of his clinical practice is advanced cellular therapies, particularly CAR-T cell immunotherapy and hematopoietic stem cell transplantation (HSCT). He has extensive experience in autologous and allogeneic stem cell transplantation, including procedures using fully HLA-matched and haploidentical (partially matched) donors. Under his leadership, the department established haploidentical transplantation and CAR-T therapy programs, including the prophylactic use of CAR-T cells after transplantation to reduce the risk of disease relapse.
Dr. Zhao also specializes in individualized treatment strategies for relapsed and refractory hematological malignancies, integrating cellular immunotherapy, targeted therapies, and transplantation techniques. His clinical expertise additionally includes the diagnosis and treatment of aplastic anemia, immune-mediated cytopenias, hemolytic anemia, thrombocytopenia, and other disorders of hematopoiesis.
He serves as a doctoral supervisor in Internal Medicine at Nankai University and Tianjin Medical University and is a review expert for the National Natural Science Foundation of China. He has led more than 10 research projects and published over 140 scientific papers, including more than 50 publications in international journals such as Blood, Leukemia, Haematologica, and Clinical Cancer Research.
His professional honors include the Second Prize of the Tianjin Science and Technology Progress Award (2020), the inaugural Tianjin "Jinmen Medical Talent" Award (2018), and the Third Prize of the Tianjin Science and Technology Progress Award (2013).
Reviews